TriSalus Life Sciences (TLSI) Set to Announce Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI) is scheduled to be releasing its earnings data before the market opens on Monday, April 1st. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $9.75 on Friday. The business has a fifty day moving average of $9.40 and a two-hundred day moving average of $7.00. TriSalus Life Sciences has a 52-week low of $3.32 and a 52-week high of $16.24.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. UBS Group AG purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at $128,000. Cambridge Investment Research Advisors Inc. purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at $131,000. Northern Trust Corp purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at $154,000. Creative Planning purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at $137,000. Finally, Vanguard Group Inc. purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at $1,395,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.